Corteria https://corteriapharma.com/ Interceptive therapies for the treatment of heart failure, sarcopenia and obesity subpopulations Mon, 21 Jul 2025 15:36:23 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://corteriapharma.com/wp-content/uploads/2022/12/cropped-favicon-corteria-32x32.png Corteria https://corteriapharma.com/ 32 32 Corteria announces significant progresses with the two first-in-class CRF2 agonists https://corteriapharma.com/news/corteria-announces-significant-progresses-with-the-two-first-in-class-crf2-agonists/ Mon, 21 Jul 2025 11:37:19 +0000 https://corteriapharma.com/?p=1785 COR-1167 is entering Phase 2 clinical trial for the treatment of Worsening Heart Failure after obtaining promising Phase 1 data, while the Phase 1 of COR-1389 is ongoing for the treatment of Obesity and Right Heart Failure. Philip Janiak, Corteria’s CEO said:“The robust preclinical data, together with the emerging clinical data, strengthen our confidence as […]

The post Corteria announces significant progresses with the two first-in-class CRF2 agonists appeared first on Corteria.

]]> COR-1167 is entering Phase 2 clinical trial for the treatment of Worsening Heart Failure after obtaining promising Phase 1 data, while the Phase 1 of COR-1389 is ongoing for the treatment of Obesity and Right Heart Failure.

Philip Janiak, Corteria’s CEO said:“The robust preclinical data, together with the emerging clinical data, strengthen our confidence as we move into Phase 2 and expand our footprint in cardiometabolic diseases.” 

Full PR is available here :https://corteriapharma.com/wp-content/uploads/2025/07/250721-Corteria-CRF2-trials-EN.pdf

The post Corteria announces significant progresses with the two first-in-class CRF2 agonists appeared first on Corteria.

]]> AHA 2024 https://corteriapharma.com/news/aha-2024/ Tue, 17 Dec 2024 09:20:56 +0000 https://corteriapharma.com/?p=1681 Two communications have been made at the AHA 2024 in Chicago on COR-1167 and COR-1389:

The post AHA 2024 appeared first on Corteria.

]]> Two communications have been made at the AHA 2024 in Chicago on COR-1167 and COR-1389:

  • COR-1389:  Data presented indicated that our long-acting CRF2 receptor agonist, COR-1389, improved cardiopulmonary function and the adverse maladaptive cardiac remodeling in the rat model of Sugen plus hypoxia-induced pulmonary arterial hypertension and right heart failure.
  • COR-1167: In the setting of WHF rat model, COR-1167 administered on top of an SGLT2 inhibitor significantly improved cardiac function, perfusion and energetics as well as natriuresis and diuresis.

The post AHA 2024 appeared first on Corteria.

]]> ESC 2024 https://corteriapharma.com/news/esc-2024/ Tue, 17 Dec 2024 09:12:11 +0000 https://corteriapharma.com/?p=1678 New preclinical data of COR-1389 in a model of right heart failure (RHF) were presented at the ESC 2024 in London.  Chronic CRF2 agonism with COR-1389 improved dysregulated cardiac and pulmonary function and structure in a RHF rat model, suggesting its potential for the treatment of PH and RHF.

The post ESC 2024 appeared first on Corteria.

]]> New preclinical data of COR-1389 in a model of right heart failure (RHF) were presented at the ESC 2024 in London.  Chronic CRF2 agonism with COR-1389 improved dysregulated cardiac and pulmonary function and structure in a RHF rat model, suggesting its potential for the treatment of PH and RHF.

The post ESC 2024 appeared first on Corteria.

]]> ESC Heart Failure 2024 https://corteriapharma.com/news/esc-heart-failure-2024/ Fri, 28 Jun 2024 12:39:24 +0000 https://corteriapharma.com/?p=1628 At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac filling and venous pressures, increased diuresis, decreased body weight and improved renal function in a worsening heart failure sheep model, even under conditions of fluid overload. […]

The post ESC Heart Failure 2024 appeared first on Corteria.

]]> At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac filling and venous pressures, increased diuresis, decreased body weight and improved renal function in a worsening heart failure sheep model, even under conditions of fluid overload. COR-1167 represents a promising new treatment for WHF.

The post ESC Heart Failure 2024 appeared first on Corteria.

]]> Corteria annonces the First-in-Human study of COR-1167 https://corteriapharma.com/news/corteria-annonces-the-first-in-human-study-of-cor-1167/ Tue, 26 Mar 2024 10:26:00 +0000 https://corteriapharma.com/?p=1558 Corteria team is very proud to announce the initiation of COR-1167 first-in-human study. COR-1167 is a first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist. A significant milestone toward a treatment for worsening heart failure. Full PR is available here :https://corteriapharma.com/wp-content/uploads/2024/03/Corteria-PR-FIM-COR-1167-EN.pdf

The post Corteria annonces the First-in-Human study of COR-1167 appeared first on Corteria.

]]> Corteria team is very proud to announce the initiation of COR-1167 first-in-human study. COR-1167 is a first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist. A significant milestone toward a treatment for worsening heart failure.


Full PR is available here :https://corteriapharma.com/wp-content/uploads/2024/03/Corteria-PR-FIM-COR-1167-EN.pdf

The post Corteria annonces the First-in-Human study of COR-1167 appeared first on Corteria.

]]> Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors https://corteriapharma.com/news/mark-pruzanski-appointment/ Mon, 08 Jan 2024 10:28:40 +0000 https://corteriapharma.com/?p=1542 Paris (France), 05 January 2024 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Directors. He replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the Board. […]

The post Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors appeared first on Corteria.

]]> Paris (France), 05 January 2024 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Directors. He replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the Board.

Full PR is available here :https://corteriapharma.com/wp-content/uploads/2024/01/Corteria-PR-appointment-Chairman_Final.pdf

The post Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors appeared first on Corteria.

]]> AHA 2023 https://corteriapharma.com/news/aha-2023/ Wed, 15 Nov 2023 16:44:26 +0000 https://corteriapharma.com/?p=1531 At AHA 2023, the last results of COR-1167 in a sheep model of Worsening Heart Failure, developed by M. Rademaker (Univ. Otago, NZ) were presented: Furosemide at a dose that promotes natriuresis/diuresis had no effect on cardiac pressures or function. The combination of COR-1167 plus furosemide reduced Left Atrial Pressure, Left Ventricular End Diastolic Pressure […]

The post AHA 2023 appeared first on Corteria.

]]> At AHA 2023, the last results of COR-1167 in a sheep model of Worsening Heart Failure, developed by M. Rademaker (Univ. Otago, NZ) were presented: Furosemide at a dose that promotes natriuresis/diuresis had no effect on cardiac pressures or function. The combination of COR-1167 plus furosemide reduced Left Atrial Pressure, Left Ventricular End Diastolic Pressure and plasma BNP, and increased Cardiac Output and natriuresis, without affecting Systolic Blood Pressure. The CRF2 receptor agonist, COR-1167, is a potential new treatment for HF.

The post AHA 2023 appeared first on Corteria.

]]> Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases https://corteriapharma.com/news/corteria-pharmaceuticals-announces-a-e65m-financing-to-advance-transformational-medicines-in-cardiovascular-diseases/ Thu, 07 Sep 2023 14:12:44 +0000 https://corteriapharma.com/?p=1493 Paris (France), 07 September 2023 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma Partners, […]

The post Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases appeared first on Corteria.

]]> Paris (France), 07 September 2023 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, Omnes Capital). As a result, Erez Chimovits from OrbiMed and Andreas Wallnoefer from Jeito Capital will join the board of Directors of Corteria.

Full PR is available here : https://corteriapharma.com/wp-content/uploads/2023/09/Serie-APR_EN.pdf

The post Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases appeared first on Corteria.

]]> ESC 2023 https://corteriapharma.com/news/esc-2023/ Wed, 30 Aug 2023 14:56:17 +0000 https://corteriapharma.com/?p=1465 At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time ! COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor agonists […]

The post ESC 2023 appeared first on Corteria.

]]> At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time !
COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor agonists potentially offer new therapeutic options for the treatment of  heart failure.

The post ESC 2023 appeared first on Corteria.

]]> Corteria: a new strategy and approach to treating heart failure https://corteriapharma.com/news/corteria-a-new-strategy-and-approach-to-treating-heart-failure/ Mon, 15 May 2023 11:55:49 +0000 https://corteriapharma.com/?p=1457 Instead of targeting broad heterogenous chronic heart failure populations, at Corteria, we are addressing well defined heart failure subpopulations that are most likely to benefit from our treatments: learn more about Corteria Pharmaceuticals strategy and portfolio at https://lnkd.in/gncbAv4r

The post Corteria: a new strategy and approach to treating heart failure appeared first on Corteria.

]]> Instead of targeting broad heterogenous chronic heart failure populations, at Corteria, we are addressing well defined heart failure subpopulations that are most likely to benefit from our treatments: learn more about Corteria Pharmaceuticals strategy and portfolio at https://lnkd.in/gncbAv4r

The post Corteria: a new strategy and approach to treating heart failure appeared first on Corteria.

]]>